About Netrin-3
Netrin-3 (NTN3) is a protein
from Homo sapiens identified by UniProt accession
O00634, 580 residues long.
MolForge cross-references it against 0 known binders and
14 disease associations.
Target properties
| Protein name | Netrin-3 |
| UniProt accession | O00634 |
| Gene | NTN3 |
| Organism | Homo sapiens |
| Length | 580 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (14)
Diseases linked to this target (Open Targets).
- hip circumference · score 0.09
- mean reticulocyte volume · score 0.03
- trigeminal neuralgia · score 0.03
- sitting height measurement · score 0.02
- cancer · score 0.01
- nonpapillary renal cell carcinoma · score 0.01
- neoplasm · score 0.01
- Autosomal dominant polycystic kidney disease · score 0.01
- small cell lung carcinoma · score 0.01
- prostate adenocarcinoma · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O00634-F1 | alphafold | PREDICTED | 87.19 | — |
Amino-acid sequence (580 residues)
MPGWPWGLLL TAGTLFAALS PGPPAPADPC HDEGGAPRGC VPGLVNAALG REVLASSTCG RPATRACDAS DPRRAHSPAL LTSPGGTASP LCWRSESLPR APLNVTLTVP LGKAFELVFV SLRFCSAPPA SVALLKSQDH GRSWAPLGFF SSHCDLDYGR LPAPANGPAG PGPEALCFPA PLAQPDGSGL LAFSMQDSSP PGLDLDSSPV LQDWVTATDV RVVLTRPSTA GDPRDMEAVV PYSYAATDLQ VGGRCKCNGH ASRCLLDTQG HLICDCRHGT EGPDCGRCKP FYCDRPWQRA TARESHACLA CSCNGHARRC RFNMELYRLS GRRSGGVCLN CRHNTAGRHC HYCREGFYRD PGRALSDRRA CRACDCHPVG AAGKTCNQTT GQCPCKDGVT GLTCNRCAPG FQQSRSPVAP CVKTPIPGPT EDSSPVQPQD CDSHCKPARG SYRISLKKFC KKDYAVQVAV GARGEARGAW TRFPVAVLAV FRSGEERARR GSSALWVPAG DAACGCPRLL PGRRYLLLGG GPGAAAGGAG GRGPGLIAAR GSLVLPWRDA WTRRLRRLQR RERRGRCSAA
Explore Netrin-3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets